01/04/2026

We are delighted to announce that EchoPoint Medical has secured a $2.5M investment round led by Parkwalk, with participation from UCL Technology Fund. This funding is a huge catalyst for us. We’re advancing directly toward our FDA submission and initiating our US clinical program to generate real-world evidence and show the iKOr system’s ability to measure coronary blood flow and pressure.  
 
Our mission is to make comprehensive coronary physiology assessment clinically practical and more consistent compared to other devices on the market. Our iKOr platform aims to deliver a true, consistent deep dive into the entire coronary physiology including critical, often overlooked issues within the microvasculature, all within seconds. 
 
A huge thank you to our investors for their continued belief and support. We are extremely excited to begin our clinical program and take these steps to transform coronary physiology diagnosis.